EGFR and non-small cell lung carcinoma: Osimertinib, a third-generation of EGFR-TKI, has been shown to significantly and sustainably increase the expression of both TGF-β1 and αvβ3 integrin in in vitro and in vivo models of EGFR-mutant lung cancer (HCC827 NSCLC cells) with acquired resistance to osimertinib [106].